What precaution should women taking binimetinib and encorafenib follow?

• A. Use birth control
• B. Avoid exercise
• C. Follow a high-fiber diet
• D. Avoid sun exposure

Answer: (A)

Preventing fetal exposure to teratogenic cancer therapies. Encorafenib and binimetinib can harm a developing fetus, so women of reproductive potential should use effective contraception during treatment to avoid pregnancy. This precaution helps protect a potential pregnancy from the risks posed by these drugs and is typically advised for a period after stopping therapy as guided by the clinician.

Other options aren’t the primary safety focus for this scenario. For example, sun exposure concerns can arise with some MEK inhibitors due to photosensitivity, but contraception specifically addresses the risk of fetal harm. Diet or exercise guidelines aren’t the key safety requirement linked to these agents.